DNM1L and hereditary spastic paraplegia: In hereditary spastic paraplegias (HSPs), the inhibition of Drp1 by a selective peptide inhibitor P110 or genetic depletion of Drp1 rescued axonal and neuronal degeneration in human iPSC derived from the fibroblasts of patients with the SPG11 mutation, implicating mitochondrial dynamics in neurodegeneration (Chen et al., 2022).